We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 as of February 9th. TVTX’s forward P/E was 26.32 respectively according to Yahoo Finance. 7 Best Dialysis and Kidney Disease Stocks to Buy yezry/Shutterstock.com Travere Therapeutics (TVTX) is a biotech company focused on rare kidney and metabolic diseases, with its lea ...

We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 as of February 9th. TVTX’s forward P/E was 26.32 respectively according to Yahoo Finance. 7 Best Dialysis and Kidney Disease Stocks to Buy yezry/Shutterstock.com Travere Therapeutics (TVTX) is a biotech company focused on rare kidney and metabolic diseases, with its lea ...

分组1 - Travere Therapeutics reported 4Q25 non-GAAP EPS of $0.37, aligning with expectations [1] - Revenue for the quarter was $129.6 million, representing a 73% year-over-year increase, but fell short of consensus by approximately $18 million [1]

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, highlighting significant growth for its flagship medication, Filspari. The company achieved quarterly net product sales of $126.6 million and a full-year total of $410.5 million, with Filspari alone generating $322 million in 2025, which was a 144% increase year-over-year. This growth was supported by expanded physicia ...

Heerma attributed fourth-quarter momentum to several factors, including FILSPARI’s differentiated profile as a once-daily oral, non-immunosuppressive therapy; simplified REMS monitoring requirements ; and the publication of KDIGO guidelines . He also said adoption is increasing in IgAN patients with proteinuria levels below 1.5 grams per gram, consistent with guideline direction toward earlier intervention and lower targets. When asked to quantify what proportion of fourth-quarter patient start forms came f ...

Core Insights - Travere Therapeutics reported a revenue of $129.69 million for the quarter ended December 2025, reflecting a year-over-year increase of 73.4% [1] - The earnings per share (EPS) was $0.03, a significant improvement from -$0.73 in the same quarter last year, with an EPS surprise of +16.73% [1] - The reported revenue was below the Zacks Consensus Estimate of $142.46 million, resulting in a revenue surprise of -8.97% [1] Revenue Breakdown - Revenue from Tiopronin products / Thiola was $23.27 million, slightly above the estimated $21.9 million, but a decrease of 2.6% compared to the previous year [4] - Total net product sales reached $126.61 million, exceeding the average estimate of $125.35 million, marking a year-over-year increase of 72.2% [4] - Revenue from FILSPARI was $103.34 million, slightly above the estimated $103.05 million, representing a substantial increase of 108.2% year-over-year [4] - License and collaboration revenue was reported at $3.08 million, significantly lower than the average estimate of $15.33 million, but still showing a year-over-year increase of 148.3% [4] Stock Performance - Over the past month, shares of Travere have returned -1.4%, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

分组1 - Travere Therapeutics reported quarterly earnings of $0.03 per share, aligning with the Zacks Consensus Estimate, compared to a loss of $0.73 per share a year ago, representing an earnings surprise of +16.73% [1] - The company posted revenues of $129.69 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 8.97%, and this is an increase from year-ago revenues of $74.79 million [2] - Travere has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed, losing about 27.1% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.07 on $135 million in revenues, and for the current fiscal year, it is $0.62 on $673.01 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Travere Therapeutics (NasdaqGM:TVTX) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsBill Rote - Chief Research OfficerChris Cline - CFOEric Dube - President and CEOGavin Clark-Gartner - Managing Director of Biotechnology Equity ResearchJason Zemansky - Managing DirectorJula Inrig - Chief Medical OfficerNivi Nehra - VP of Corporate Communications and Investor RelationsPeter Heerma - Chief Commercial OfficerConference Call ParticipantsAlex Thompson - Managing Director and Senior Equit ...

Travere Therapeutics (NasdaqGM:TVTX) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsBill Rote - Chief Research OfficerChris Cline - CFOEric Dube - President and CEOGavin Clark-Gartner - Managing Director of Biotechnology Equity ResearchJason Zemansky - Managing DirectorJula Inrig - Chief Medical OfficerNivi Nehra - VP of Corporate Communications and Investor RelationsPeter Heerma - Chief Commercial OfficerConference Call ParticipantsAlex Thompson - Managing Director and Senior Equit ...

Travere Therapeutics (NasdaqGM:TVTX) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Speaker3Good afternoon, and welcome to the Travere Therapeutics fourth quarter and full year 2025 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nehra, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi.Speaker4Thank you, operator. Good afternoon, and welcome to Travere Therapeutics' fourth quarter ...